{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.7","value":"58.4"}]}],"title":"Future perspective"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.4","value":"72.9"}]}],"title":"Body image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.2","value":"30.7"}]}],"title":"Symptoms of the disease"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.2","value":"25.4"}]}],"title":"Adverse effects of the treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"273"}],"units":"Participants"}],"description":"The EORTC QLQ-MY20 has 20 items across 4 independent subscales, 2 functional subscales (body image, future perspective), and 2 symptoms scales (disease symptoms, and side effects of treatment) with a recall period of previous week. Scores from each subscale were transformed from 0 to 100. For the functional scales, high scores represent improvement. For the symptom scales, higher scores represent worsening.","dispersionType":"Standard Deviation","groups":[{"description":"Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.","id":"OG000","title":"Multiple Myeloma (MM) Participants"}],"paramType":"MEAN","populationDescription":"All participants eligible for analyses were included. Overall number of participants analyzed are the participants with data available for analyses.","reportingStatus":"POSTED","timeFrame":"Day 1","title":"HRQOL Based on EORTC Multiple Myeloma Module (EORTC QLQ-MY20) Subscale Score","type":"SECONDARY","unitOfMeasure":"score on scale"}